EichorEICHOR
Location: Crowley Synced from ClinicalTrials.gov · August 10, 2026

Clinical studies recruiting near Crowley

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced
Phase 1 · Kumquat Biosciences Inc. · NCT06994806A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 · Clasp Therapeutics, Inc. · NCT06778863A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Phase 1 · Peel Therapeutics Inc · NCT05329103Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · Impact Therapeutics, Inc. · NCT05269316A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · Artios Pharma Ltd · NCT04657068A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · Context Therapeutics Inc. · NCT06515613Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · Revolution Medicines, Inc. · NCT05379985Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · Revolution Medicines, Inc. · NCT06128551Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Phase 1 · BioNTech SE · NCT06750185A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · Iambic Therapeutics, Inc · NCT06253871A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 · Astellas Pharma Global Development, Inc. · NCT05719558A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1 · CStone Pharmaceuticals · NCT05279300A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Phase 1 · Abbisko Therapeutics Co, Ltd · NCT05244551A Study of LM-24C5 For Advanced Solid Tumors
Phase 1/Phase 2 · LaNova Medicines Limited · NCT06187402Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · Revolution Medicines, Inc. · NCT06040541Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Phase 1 · Janux Therapeutics · NCT05519449A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · ImmVira Pharma Co. Ltd · NCT04370587Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · I-Mab Biopharma US Limited · NCT04900818A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · Apollo Therapeutics Ltd · NCT06399757A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Phase 2 · Cybrexa Therapeutics · NCT06315491AMT-116 in Patients With Advanced Solid Tumors
Phase 1 · Multitude Therapeutics Inc. · NCT05725291A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Phase 1 · Whitehawk Therapeutics, Inc. · NCT07470853Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2 · Boehringer Ingelheim · NCT06581432Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Phase 1/Phase 2 · Qurient Co., Ltd. · NCT05394103Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Phase 1 · Novartis Pharmaceuticals · NCT07604571Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Phase 1 · Gilead Sciences · NCT05007782HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Phase 1 · HighField Biopharmaceuticals Corporation · NCT05861895A Study of TAK-505 in Adults With Solid Tumors
Phase 1/Phase 2 · Takeda · NCT07436728Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Meta
Phase 1/Phase 2 · Inhibrx Biosciences, Inc · NCT04198766Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Phase 3 · BriaCell Therapeutics Corporation · NCT06072612
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.